Impairing memory reconsolidation with propranolol in healthy and clinical samples: a meta-analysis

J Psychiatry Neurosci. 2022 Mar 31;47(2):E109-E122. doi: 10.1503/jpn.210057. Print 2022 Mar-Apr.

Abstract

Background: Reconsolidation impairment using propranolol is a novel intervention for mental disorders with an emotional memory at their core. In this systematic review and meta-analysis, we examined the evidence for this intervention in healthy and clinical adult samples.

Methods: We searched 8 databases for randomized, double-blind studies that involved at least 1 propranolol group and 1 placebo group. We conducted a meta-analysis of 14 studies (n = 478) in healthy adults and 12 studies in clinical samples (n = 446).

Results: Compared to placebo, reconsolidation impairment under propranolol resulted in reduced recall of aversive material and cue-elicited conditioned emotional responses in healthy adults, as evidenced by an effect size (Hedges g) of -0.51 (p = 0.002, 2-tailed). Moreover, compared to placebo, reconsolidation impairment under propranolol alleviated psychiatric symptoms and reduced cue-elicited reactivity in clinical samples with posttraumatic stress disorder, addiction or phobia (g = -0.42, p = 0.010).

Limitations: Methodological differences between studies posed an obstacle for identifying sources of heterogeneity.

Conclusion: Reconsolidation impairment is a robust, well-replicated phenomenon in humans. Its clinical use is promising and deserves further controlled investigation.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists* / pharmacology
  • Adult
  • Emotions
  • Humans
  • Mental Recall / physiology
  • Propranolol* / pharmacology
  • Propranolol* / therapeutic use
  • Randomized Controlled Trials as Topic

Substances

  • Adrenergic beta-Antagonists
  • Propranolol